- Home
- ARDX
ARDX
Ardelyx Inc.
as of 02-26-2026 3:38pm EST
$6.66
+$0.10
+1.45%
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.6B | IPO Year: | 2014 |
| Target Price: | $14.67 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | -52.94 |
| 52 Week Low/High: | $3.50 - $8.40 | Next Earning Date: | 05-12-2026 |
| Revenue: | $2,607,000 | Revenue Growth: | -93.79% |
| Revenue Growth (this year): | 35.64% | Revenue Growth (next year): | 34.12% |
| P/E Ratio: | -25.23 | Index: | N/A |
| Free Cash Flow: | -43975000.0 | FCF Growth: | N/A |
AI-Powered ARDX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 66.67%
66.67%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
RAAB MICHAEL
Sell
President & CEO
ARDX Feb 24, 2026
Avg Cost/Share
$6.26
Shares
41,666
Total Value
$260,620.83
Owned After
1,836,153
SEC Form 4
MOTT DAVID M
Buy
Director
ARDX Feb 20, 2026
Avg Cost/Share
$5.84
Shares
333,333
Total Value
$1,946,331.39
Owned After
3,302,918
SEC Form 4
RAAB MICHAEL
Sell
President & CEO
ARDX Feb 20, 2026
Avg Cost/Share
$5.74
Shares
45,982
Total Value
$268,840.52
Owned After
1,836,153
Williams Laura A
Sell
See Remarks
ARDX Feb 20, 2026
Avg Cost/Share
$5.79
Shares
8,176
Total Value
$47,803.46
Owned After
437,066
Bishop John E
Sell
See Remarks
ARDX Feb 20, 2026
Avg Cost/Share
$5.76
Shares
3,179
Total Value
$18,586.31
Owned After
339,152
Kelliher Mike
Sell
See Remarks
ARDX Feb 20, 2026
Avg Cost/Share
$5.76
Shares
9,595
Total Value
$56,099.11
Owned After
364,666
Foster Eric Duane
Sell
Chief Commercial Officer
ARDX Feb 20, 2026
Avg Cost/Share
$5.75
Shares
10,439
Total Value
$61,033.75
Owned After
425,970
Reilly Joseph James
Sell
See Remarks
ARDX Feb 20, 2026
Avg Cost/Share
$5.76
Shares
4,991
Total Value
$29,180.86
Owned After
151,792
Hohenleitner Susan
Sell
Chief Financial Officer
ARDX Feb 20, 2026
Avg Cost/Share
$5.79
Shares
2,033
Total Value
$11,886.20
Owned After
230,533
Brady James Parker
Sell
Chief Human Resources Officer
ARDX Feb 20, 2026
Avg Cost/Share
$5.79
Shares
2,543
Total Value
$14,867.97
Owned After
263,221
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | Feb 24, 2026 | Sell | $6.26 | 41,666 | $260,620.83 | 1,836,153 | |
| MOTT DAVID M | ARDX | Director | Feb 20, 2026 | Buy | $5.84 | 333,333 | $1,946,331.39 | 3,302,918 | |
| RAAB MICHAEL | ARDX | President & CEO | Feb 20, 2026 | Sell | $5.74 | 45,982 | $268,840.52 | 1,836,153 | |
| Williams Laura A | ARDX | See Remarks | Feb 20, 2026 | Sell | $5.79 | 8,176 | $47,803.46 | 437,066 | |
| Bishop John E | ARDX | See Remarks | Feb 20, 2026 | Sell | $5.76 | 3,179 | $18,586.31 | 339,152 | |
| Kelliher Mike | ARDX | See Remarks | Feb 20, 2026 | Sell | $5.76 | 9,595 | $56,099.11 | 364,666 | |
| Foster Eric Duane | ARDX | Chief Commercial Officer | Feb 20, 2026 | Sell | $5.75 | 10,439 | $61,033.75 | 425,970 | |
| Reilly Joseph James | ARDX | See Remarks | Feb 20, 2026 | Sell | $5.76 | 4,991 | $29,180.86 | 151,792 | |
| Hohenleitner Susan | ARDX | Chief Financial Officer | Feb 20, 2026 | Sell | $5.79 | 2,033 | $11,886.20 | 230,533 | |
| Brady James Parker | ARDX | Chief Human Resources Officer | Feb 20, 2026 | Sell | $5.79 | 2,543 | $14,867.97 | 263,221 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
GuruFocus.com
Ardelyx Inc (ARDX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Developments ...
📊
AI Sentiment
Positive
6/10
Compare ARDX vs Leading Stocks
See how ARDX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.